is a glp 1 a peptide Glucagon-like in health and disease GLP-1 (9-36), Glucagon-like Peptide 1

However, it corroborates the medical necessity for the infusion

Essentially zero

The 5-day half-life and weekly dosing schedule may improve medication adherence compared to daily injectable therapies, which is particularly valuable for patients with type 2 diabetes who often manage multiple medications

That opportunity is now supported by manufacturing commitments, including Novo Nordisk's March 2026 announcement of a EUR 432 million expansion in Athlone, Ireland, to increase capacity for oral GLP-1 therapies, alongside Eli Lilly's November 2025 plan to build a USD 3 billion manufacturing facility in Katwijk, the Netherlands, aimed at oral medicines including the GLP-1 receptor agonist orforglipron